Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

Decoy Therapeutics Inc. DCOY

· Materials · Pharmaceutical Preparations

Fundamentals
SEC EDGAR

Filing evidence summary

Caution evidenceCoverage 2/5 core metrics

Latest reported free cash flow was -$5M.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Free cash flow was negative

    Latest reported free cash flow was -$5M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.

  • 1 filing risk check flagged

    Flagged areas: Solvency & liquidity.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

Core trend metrics

Free cash flow
-$5M
as of 2025-12-31
ROIC snapshot
-230.6%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

1of 5 rule-based checks flagged
  • Solvency & liquidity

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-31prior period 2024-12-31 from the same filingView filing
By business segment
Operating income
  • Reportable Segment-$12.6M
    100.0%
    +120.0% yoy

Members sum to the consolidated -$12.6M for this period.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,007 US-listed filers · 781 in Materials
MetricValuevs all filersvs sector
Return on equity
net income ÷ stockholders' equity (positive equity only)
-212.6%
5thof 3,576
bottom third
11thof 701
bottom third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

Not available for DCOY yet: Earnings-quality fields arrive with this issuer's next re-crawl (sec_screen_v6)..

Point-in-time ledger

Not available for DCOY yet: The point-in-time ledger arrives with this issuer's next re-crawl (sec_screen_v6)..

Notes by disclosure type

Not available for DCOY yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.